MAM
INZY

Meeder Asset Management’s Inozyme Pharma INZY Stock Holding History

Meeder Asset Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,210
Closed -$79.5K – 956
2024
Q3 		$79.5K Hold
15,210
– – 0.01% 314
2024
Q2 		$67.8K Buy
+15,210
New +$73.7K ﹤0.01% 307

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Meeder Asset Management's INZY Position: Q4 2024 in Review

Meeder Asset Management sold out of Inozyme Pharma (INZY) in Q4 2024, closing a stake of 15,210 shares — an estimated $79.5K sold.

Meeder Asset Management first reported a position in INZY in Q2 2024 and held it in 2 quarters. The position peaked at $79.5K in Q3 2024. 105 funds tracked by Wall St. Rank hold INZY as of Q4 2024.

  • Meeder Asset Management reported no remaining Inozyme Pharma position as of Q4 2024 after selling out during the quarter.
  • Meeder Asset Management sold 15,210 Inozyme Pharma shares in Q4 2024, an estimated $79.5K.
  • Meeder Asset Management first reported a position in Inozyme Pharma in Q2 2024 and held it in 2 quarters.
  • Meeder Asset Management's Inozyme Pharma position peaked at $79.5K in Q3 2024.
  • 105 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2024.

Based on Meeder Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.